Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jan;52(1):333-6.
doi: 10.1128/AAC.00689-07. Epub 2007 Oct 29.

Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii

Glenn A Pankuch  1 , Gengrong Lin, Harald Seifert, Peter C Appelbaum
Affiliations

Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii

Glenn A Pankuch et al. Antimicrob Agents Chemother. 2008 Jan.

Abstract

Time-kill synergy studies showed that at 24 h, subinhibitory meropenem and ciprofloxacin concentrations of 0.06 to 128 and 0.03 to 32 microg/ml, respectively, showed synergy against 34/51 Pseudomonas aeruginosa strains; subinhibitory concentrations of meropenem (0.06 to 8 microg/ml) and colistin (0.12 to 1 microg/ml) showed synergy against 13 isolates. Subinhibitory meropenem and ciprofloxacin concentrations of 0.25 to 2 and 0.12 to 16 microg/ml, respectively, showed synergy against 18/52 Acinetobacter baumannii strains at 24 h. Subinhibitory meropenem and colistin concentrations of 0.03 to 64 and 0.06 to 8 microg/ml, respectively, showed synergy against 49 strains at 24 h.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Time-kill synergy studies of meropenem combined with ciprofloxacin (A) and colistin (B) against 51 isolates of P. aeruginosa and of meropenem combined with ciprofloxacin (C) and colistin (D) against 41 and 51 strains of A. baumannii, respectively. In each pair of bars, the one on the left represents an additive effect and the one on the right represents synergy. **, Significantly higher percentage of organisms showing synergy (P < 0.001).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bajaksouzian, S., M. A. Visalli, M. R. Jacobs, and P. C. Appelbaum. 1996. Antipneumococcal activities of cefpirome and cefotaxime, alone and in combination with vancomycin and teicoplanin, determined by checkerboard and time-kill methods. Antimicrob. Agents Chemother. 40:1973-1976. - PMC - PubMed
    1. Bajaksouzian, S., M. A. Visalli, M. R. Jacobs, and P. C. Appelbaum. 1997. Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters determined by checkerboard and time-kill studies. Antimicrob. Agents Chemother. 41:1073-1076. - PMC - PubMed
    1. Cappelletty, D. M., and M. R. Rybak. 1996. Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 40:677-683. - PMC - PubMed
    1. Carlet, J., A. Ben Ali, and A. Chalfine. 2004. Epidemiology and control of antibiotic resistance in the intensive care unit. Curr. Opin. Infect. Dis. 17:309-316. - PubMed
    1. Clark, C. L., M. R. Jacobs, and P. C. Appelbaum. 1999. Activities of clinafloxacin, alone and in combination with other compounds, against 45 gram-positive and -negative organisms for which clinafloxacin MICs are high. Antimicrob. Agents Chemother. 43:2295-2298. - PMC - PubMed

Publication types